Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPHASIS: Erlotinib vs Docetaxel in Advanced Squamous Cell NSCLC
NCT01652469Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Aug 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of erlotinib, docetaxel in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started Aug 2012; status: completed.
02
Drugs
erlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01652469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652469.